Pediatric Eye Disease Investigator Group

List View | Sortable View

Manuscripts

General

1. Beck RW. The Pediatric Eye Disease Investigator Group. J AAPOS 1998;2(5):255-6 (Published).
(Manuscript (Non-Peer Reviewed)) | View Publication

2. Holmes JM, Beck RW, Kip KE, et al. Botulinum toxin treatment versus conservative management in acute traumatic sixth nerve palsy or paresis. J AAPOS 2000;4(3):145-9 (Published).
(Manuscript) | View Publication

3. Cole SR, Beck RW, Moke PS, et al. The amblyopia treatment index. J AAPOS 2001;5(4):250-4 (Published).
(Manuscript) | View Publication

4. Holmes JM, Beck RW, Kip KE, et al. Predictors of nonrecovery in acute traumatic sixth nerve palsy and paresis. Ophthalmology 2001;108(8):1457-60 (Published).
(Manuscript) | View Publication

5. Holmes JM, Beck RW, Repka MX, et al. The amblyopia treatment visual acuity testing protocol. Arch Ophthalmol 2001;119(9):1345-53 (Published).
(Manuscript) | View Publication

6. Moke PS, Turpin AH, Beck RW, et al. Computerized method of visual acuity testing: adaption of the amblyopia treatment study visual acuity testing protocol. Am J Ophthalmol 2001;132(6):903-9 (Published).
(Manuscript) | View Publication

7. Beck, RW. Clinical research in pediatric ophthalmology: the Pediatric Eye Disease Investigator Group. Curr Opin Ophthalmol 2002;13(5):337-40 (Published).
(Manuscript (Non-Peer Reviewed)) | View Publication

8. Cotter SA, Chu RH, Chandler DL, et al. Reliability of the Electronic Early Treatment Diabetic Retinopathy Study testing protocol in children 7 to < 13 years old. Am J Ophthalmol 2003;136(4):655-61 (Published).
(Manuscript) | View Publication

9. Quinn GE, Beck RW, Holmes JM, Repka MX, Pediatric Eye Disease Investigator Group. Recent advances in the treatment of amblyopia. Pediatrics 2004;133(6):1800-2 (Published).
(Manuscript) | View Publication

10. Holmes JM, Fawcett SL. Testing distance stereoacuity with the Frisby-Davis 2 (FD2) test. Am J Ophthalmol 2005;139(1):193-5 (Published).
(Manuscript) | View Publication

11. Rice ML, Birch E, Holmes JM. An abbreviated reading speed test. Optom Vis Sci 2005;82(2):128-33 (Published).
(Manuscript) | View Publication

12. Holmes JM, Repka MX, Kraker RT, Clarke MP. The treatment of amblyopia. Strabismus 2006;14(1):37-42 (Published).
(Manuscript) | View Publication

13. Holmes JM, Leske DA, Cole SR, et al. A symptom survey and quality of life questionnaire for nasolacrimal duct obstruction in children. Ophthalmology 2006;113(9):1675-80 (Published).
(Manuscript) | View Publication

14. Mohney BG, Holmes JM. An office-based scale for assessing control in intermittent exotropia. Strabismus 2006;14(3):147-50 (Published).
(Manuscript) | View Publication

15. Leske DA, Birch EE, Holmes JM. Real depth vs randot stereotests. Am J Ophthalmol 2006;142(4):699-701 (Published).
(Manuscript) | View Publication

16. Holmes JM, Birch EE, Leske DA, Fu VL, Mohney BG.. New tests of distance stereoacuity and their role in evaluating intermittent exotropia.. Ophthalmology. 2007 Jun;114(6):1215-20. (Published).
(Manuscript) | View Publication

17. Holmes JM, Strauber SF, Quinn GE, et al. Further validation of the Amblyopia Treatment Index parental questionnaire. J AAPOS 2008;12(6):581-4 (Published).
(Manuscript) | View Publication

18. Birch EE, Strauber SF, Beck RW, et al. Comparison of the Amblyopia Treatment Study HOTV and Electronic-Early Treatment of Diabetic Retinopathy Study visual acuity protocols in amblyopic children aged 5 to 11 years. J AAPOS 2009;13(1):75-8 (Published).
(Manuscript) | View Publication

19. Repka MX, Simons K, Kraker R, Pediatric Eye Disease Investigator Group. Laterality of amblyopia. Am J Ophthalmol. 2010;150(2):270-4. (Published).
(Manuscript) | View Publication

20. Frick KD, Hariharan L, Repka MX, Chandler D, Melia BM, Beck RW, for the Pediatric Eye Disease Investigator Group. Cost-effectiveness of 2 Approaches to Managing Nasolacrimal Duct Obstruction in Infants: The Importance of the Spontaneous Resolution Rate. Arch Ophthalmol. 2011; 129(5):603-9. (Published).
(Manuscript) | View Publication

21. Holmes JM, Lazar EL, Melia BM, Astle WF, Dagi LR, Donahue SP, Frazier MG, Hertle RW, Repka MX, Quinn GE, Weise KK, for the Pediatric Eye Disease Investigator Group. Effect of Age on Response to Amblyopia Treatment in Children. Arch Ophthalmol. 2011;129(11):1451-7. Epub 2011 Jul 11. (Published).
(Manuscript) | View Publication

22. Wallace DK, Lazar EL, Melia M, Birch EE, Holmes JM, Hopkins KB, Kraker RT, Kulp MT, Pang Y, Repka MX, Tamkins SM, Weise KK, on behalf of the Pediatric Eye Disease Investigator Group. Stereoacuity in Children with Anisometropic Amblyopia. J AAPOS 2011;15(5):455-61. (Published).
(Manuscript) | View Publication

Protocol A10 - Bangerter Filter Treatment Study

1. Pediatric Eye Disease Investigator Group. A randomized trial comparing Bangerter filters and patching for the treatment of moderate amblyopia in children. Ophthalmology. 2010 May;117(5):998-1004.e6. Epub 2010 Feb 16. (Published).
(Manuscript) | View Publication

2. Rutstein RP, Foster NC, Cotter SA, et al., Pediatric Eye Disease Investigator Group. Visual acuity through Bangerter filters in nonamblyopic eyes. J AAPOS. 15(2):131-4. Epub 2011 Mar 21. (Published).
(Manuscript) | View Publication

Protocol A11 - Residual Amblyopia Treatment Study

1. Pediatric Eye Disease Investigator Group. A Randomized Trial to Evaluate Combined Patching and Atropine for Residual Amblyopia. Arch Ophthalmol 2011;129(7):960-2 (Published).
(Manuscript) | View Publication

Protocol A12 - Vision Therapy Treatment Study

1. Lyon DW, Hopkins K, Chu RH, Tamkins SM, Cotter SA, Melia M, Holmes JM, Repka MX, Wheeler DT, Sala NA, Dumas JD, Silbert DI, on behalf of Pediatric Eye Disease Investigator Group. Feasibility of a clinical trial of vision therapy for treatment of amblyopia. Optom Vis Sci 2013;90(5):475-81. (Published).
(Manuscript) | View Publication

Protocol ATS05 - Amblyopia Treatment Study 5

1. Pediatric Eye Disease Investigator Group. A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children. Ophthalmology 2006;113(6):904-12 (Published).
(Manuscript) | View Publication

2. Pediatric Eye Disease Investigator Group. Treatment of anisometropic amblyopia in children with refractive correction. Ophthalmology 2006;113(6):895-903 (Published).
(Manuscript) | View Publication

3. Pediatric Eye Disease Investigator Group. Treatment of strabismic amblyopia with refractive correction. Am J Ophthalmol 2007;143(6):1060-3 (Published).
(Manuscript) | View Publication

Protocol ATS06 - Amblyopia Treatment Study 6

1. Pediatric Eye Disease Investigator Group. A randomized pilot study of near activities versus non-near activities during patching therapy for amblyopia. J AAPOS 2005;9(2):129-36 (Published).
(Manuscript) | View Publication

2. Pediatric Eye Disease Investigator Group. A randomized trial of near versus distance activities while patching for amblyopia in children aged 3 to less than 7 years. Ophthalmology 2008;115(11):2071-8 (Published).
(Manuscript) | View Publication

Protocol ATS07 - Amblyopia Treatment Study 7

1. Pediatric Eye Disease Investigator Group. Treatment of bilateral refractive amblyopia in children three to less than 10 years of age. Am J Ophthalmol 2007;144(4):487-96 (Published).
(Manuscript) | View Publication

Protocol ATS08 - Amblyopia Treatment Study 8

1. Pediatric Eye Disease Investigator Group. Pharmacologic plus optical penalization treatment for amblyopia: results of a randomized trial. Arch Ophthalmol 2009;127(1):22-30 (Published).
(Manuscript) | View Publication

2. Repka MX, Kraker RT, Beck RW, et al. Treatment of severe amblyopia with atropine: results from two randomized clinical trials. J AAPOS 2009;13(3):258-63 (Published).
(Manuscript) | View Publication

Protocol ATS09 - Amblyopia Treatment Study 9

1. Pediatric Eye Disease Investigator Group. Patching vs atropine to treat amblyopia in children aged 7 to 12 years: a randomized trial. Arch Ophthalmol 2008;126(12):1634-42 (Published).
(Manuscript) | View Publication

3. Repka MX, Kraker RT, Tamkins SM, et al. Retinal nerve fiber layer thickness in amblyopic eyes. Am J Ophthalmol 2009;148(1):143-7 (Published).
(Manuscript) | View Publication

4. Felius J, Chandler DL, Holmes JM, et al. Pediatric Eye Disease Investigator Group. Evaluating the Burden of Amblyopia Treatment from the Parent and Child’s Perspective. J AAPOS. 2010; 14(5):389-95. (Published).
(Manuscript) | View Publication

Protocol ATS1 - Amblyopia Treatment Study 1

1. Pediatric Eye Disease Investigator Group. A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children. Arch Ophthalmol 2002;120(3):268-78 (Published).
(Manuscript) | View Publication

2. Pediatric Eye Disease Investigator Group. The clinical profile of moderate amblyopia in children younger than 7 years. Arch Ophthalmol 2002;120(3):281-7 (Published).
(Manuscript) | View Publication

3. Pediatric Eye Disease Investigator Group. A comparison of atropine and patching treatments for moderate amblyopia by patient age, cause of amblyopia, depth of amblyopia, and other factors. Ophthalmology 2003;110(8):1632-7; discussion 1637-8 (Published).
(Manuscript) | View Publication

4. Pediatric Eye Disease Investigator Group. The course of moderate amblyopia treated with atropine in children: experience of the amblyopia treatment study. Am J Ophthalmol 2003;136(4):630-9 (Published).
(Manuscript) | View Publication

5. Pediatric Eye Disease Investigator Group. The course of moderate amblyopia treated with patching in children: experience of the amblyopia treatment study. Am J Ophthalmol 2003;136(4):620-9 (Published).
(Manuscript) | View Publication

6. Pediatric Eye Disease Investigator Group. Impact of patching and atropine treatment on the child and family in the amblyopia treatment study. Arch Ophthalmol 2003;121(11):1625-32 (Published).
(Manuscript) | View Publication

7. Pediatric Eye Disease Investigator Group. Two-year follow-up of a 6-month randomized trial of atropine vs patching for treatment of moderate amblyopia in children. Arch Ophthalmol 2005;123(2):149-57 (Published).
(Manuscript) | View Publication

8. Repka MX, Holmes JM, Melia BM, et al. The effect of amblyopia therapy on ocular alignment. J AAPOS 2005;9(6):542-5 (Published).
(Manuscript) | View Publication

9. Repka MX, Melia M, Eibschitz-Tsimhoni M, et al. The effect on refractive error of unilateral atropine as compared with patching for the treatment of amblyopia. J AAPOS 2007;11(3):300-2 (Published).
(Manuscript) | View Publication

10. Holmes JM, Melia M, Bradfield YS, et al. Factors associated with recurrence of amblyopia on cessation of patching. Ophthalmology 2007;114(8):1427-32 (Published).
(Manuscript) | View Publication

Protocol ATS1-Ext - Long Term Follow Up of Amblyopia Treatment (ATS1 Extension Study)

1. Pediatric Eye Disease Investigator Group. A randomized trial of atropine vs patching for treatment of moderate amblyopia: follow-up at age 10 years. Arch Ophthalmol 2008;126(8):1039-44 (Published).
(Manuscript) | View Publication

2. Repka MX, Kraker RT, Beck RW, et al. Monocular oral reading performance after amblyopia treatment in children. Am J Ophthalmol 2008;146(6):942-7 (Published).
(Manuscript) | View Publication

3. Repka MX, Kraker RT, Beck RW, et al. Contrast sensitivity following amblyopia treatment in children. Arch Ophthalmol 2009;127(9):1225-7 (Published).
(Manuscript) | View Publication

4. Kulp MT, Foster NC, Holmes JM, et al. Effect of Ocular Alignment on Emmetropization in Children <10 Years With Amblyopia. Am J Ophthalmol 2012;154(2): 297-302 (Published).
(Manuscript) | View Publication

5. Pediatric Eye Disease Investigator Group. Atropine vs patching for treatment of moderate amblyopia: follow-up at 15 years of age of a randomized clinical trial. JAMA Ophthalmol. Jul 2014;132(7):799-805. (Published).
(Manuscript) | View Publication

Protocol ATS13 - Spectacles for Strabismic Amblyopia

1. Pediatric Eye Disease Investigator Group. Optical Treatment of Strabismic and Combined Strabismic-Anisometropic Amblyopia. Ophthalmology 2011;119(1):150-8. Epub Sep 29 2011. (Published).
(Manuscript) | View Publication

Protocol ATS14 - Levodopa for Amblyopia Pilot

1. Repka MX, Kraker RT, Beck RW, et al. Pilot study of levodopa dose as treatment for residual amblyopia in children aged 8 years to younger than 18 years. Arch Ophthalmol. 2010 Sep;128(9):1215-7. (Published).
(Manuscript) | View Publication

Protocol ATS15 - Increasing Patching for Amblyopia Study

1. Pediatric Eye Disease Investigator Group. A randomized trial of increasing patching for amblyopia. Ophthalmology. 2013 Nov;120(11):2270-7. (Published).
(Manuscript) | View Publication

2. Wallace DK, Lazar EL, Crouch ER III, Hoover DL, Tamkins SM, on behalf of Pediatric Eye Disease Investigator Group. Time course and predictors of amblyopia improvement with 2 hours of daily patching. JAMA Ophthalmol. May 2015;133(5):606-609. (Published).
(Manuscript) | View Publication

Protocol ATS16 - Augmenting Atropine Treatment for Amblyopia Study

1. Pediatric Eye Disease Investigator Group. A randomized trial of adding a plano lens to atropine for amblyopia. J AAPOS. Feb 2015;19(1):42-48 (Published).
(Manuscript) | View Publication

Protocol ATS17 - Levodopa for Residual Amblyopia Study

1. Pediatric Eye Disease Investigator Group. A randomized trial of levodopa as treatment for residual amblyopia in older children. Ophthalmology. May 2015;122(5):874-881. (Published).
(Manuscript) | View Publication

Protocol ATS18 - Amblyopia Treatment Study 18

1. Pediatric Eye Disease Investigator Group. Effect of a binocular iPad game versus part-time patching in children aged 5 to 12 with amblyopia: a randomized clinical trial. JAMA Ophthalmol 2016;134(12) (Published).
(Manuscript) | View Publication

2. Manh VM, Holmes JM, Lazar EL, Kraker RT, Wallace DK, Kulp MT, Galvin JA, Shah BK, Davis PL; Pediatric Eye Disease Investigator Group. A Randomized Trial Of A Binocular iPad Game Versus Part-Time Patching In Children 13 To 16 Years Of Age With Amblyopia. Am J Ophthalmol 2018;186:104-15. (Published).
(Manuscript) | View Publication

Protocol ATS20 - Amblyopia Treatment Study 20

1. Holmes JM, Manny RE, Lazar EL, Birch EE, Kelly KR, Summers AI, Martinson SR, Raghuram A, Colburn JD, Law C, Marsh JD, Bitner DP, Kraker RT, Wallace DK, Pediatric Eye Disease Investigator Group. A Randomized Trial of Binocular Dig Rush Game Treatment for Amblyopia in Children Aged 7 to 12 Years. Ophthalmology. 2019;126(3):456-466. (Published).
(Manuscript) | View Publication

2. Manny RE, Holmes JM, Kraker RT, Li Z, Waters AL, Kelly KR, Kong L, Crouch ER, Lorenzana IJ, Alkharashi MS, Galvin JA, Rice ML, Melia BM, Cotter SA; on behalf of PEDIG. A Randomized Trial of Binocular Dig Rush Game Treatment for Amblyopia in Children Aged 4 to 6 Years of Age.. Optom Vis Sci. 2022 Mar 1;99(3):213-227. (Published).
(Manuscript) | View Publication

Protocol ATS2A - A Randomized Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia

1. Pediatric Eye Disease Investigator Group. A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children. Ophthalmology 2003;110(11):2075-87 (Published).
(Manuscript) | View Publication

Protocol ATS2B - A Randomized Trial Comparing Part-time Versus Minimal-time Patching for Moderate Amblyopia

1. Pediatric Eye Disease Investigator Group. A randomized trial of patching regimens for treatment of moderate amblyopia in children. Arch Ophthalmol 2003;121(5):603-11 (Published).
(Manuscript) | View Publication

Protocol ATS2C - Amblyopia Treatment Study 2C

1. Pediatric Eye Disease Investigator Group. Risk of amblyopia recurrence after cessation of treatment. J AAPOS 2004;8(5):420-8 (Published).
(Manuscript) | View Publication

Protocol ATS3 - Amblyopia Treatment Study 3

1. Pediatric Eye Disease Investigator Group. A prospective, pilot study of treatment of amblyopia in children 10 to < 18 years old. Am J Ophthalmol 2004;137(3):581-3 (Published).
(Manuscript) | View Publication

2. Pediatric Eye Disease Investigator Group. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol 2005;123(4):437-47 (Published).
(Manuscript) | View Publication

3. Pediatric Eye Disease Investigator Group. Stability of visual acuity improvement following discontinuation of amblyopia treatment in children aged 7 to 12 years. Arch Ophthalmol 2007;125(5):655-9 (Published).
(Manuscript) | View Publication

Protocol ATS4 - Amblyopia Treatment Study 4

1. Pediatric Eye Disease Investigator Group. A randomized trial of atropine regimens for treatment of moderate amblyopia in children. Ophthalmology 2004;111(11):2076-85 (Published).
(Manuscript) | View Publication

2. Christoff A, Repka MX, Kaminski B, Holmes JM, on behalf of the Pediatric Eye Disease Investigator Group. Distance versus Near Visual Acuity in Amblyopia. J AAPOS 2011;15(4):342-4. (Published).
(Manuscript) | View Publication

Protocol C02 - Cataract Surgery Registry

1. Repka, MX, Dean, TW,Lazar, EL,Yen, KG, Lenhart, PD, Freedman, SF, Hug, D, Rahmani, B, Wang, SX, Kraker, RT, Wallace, DK, for the Pediatric Eye Disease Investigator Group. Cataract Surgery in Children from Birth to Less than 13 Years of Age: Baseline Characteristics of the Cohort. Ophthalmology. 2016 Oct 18. pii: S0161-6420(16)31165-4 (Published).
(Manuscript) | View Publication

2. Pediatric Eye Disease Investigator Group. Visual Acuity and Ophthalmic Outcomes in the Year After Cataract Surgery Among Children Younger Than 13 Years.. JAMA Ophthalmol. 2019;137(7):817-824. (Published).
(Manuscript) | View Publication

3. Freedman SF, Kraker RT, Repka MX, Wallace DK, de Alba Campomanes A,Yanovitch TL, Orge FH,Gearinger MD for the Pediatric Eye Disease Investigator Group (PEDIG). Glaucoma or Glaucoma Suspect in the First Year After Pediatric Lensectomy. JAMA Ophthalmol. 2020;138(1):71-75 (Published).
(Manuscript) | View Publication

4. Bothun ED, Repka MX, Dean TW, Gray ME, Lenhart PD, Li Z, Morrison DG, Wallace DK, Kraker RT, Cotter SA, Holmes JM on behalf of the Pediatric Eye Disease Investigator Group.. Visual Outcomes and Complications Following Lensectomy for Traumatic Cataract in Children.. JAMA Ophthalmol. 2021;139(6):647-653. (Published).
(Manuscript) | View Publication

5. Repka MX, Dean TW, Kraker RT, Li Z, Yen KG, de Alba Campomanes AG, Young MP, Rahmani B, Haider KM, Whitehead GF, Lambert SR, Kurup SP, Kraus CL, Cotter SA, Holmes JM; on behalf of PEDIG. Visual Acuity and Ophthalmic Outcomes 5 Years After Cataract Surgery Among Children Younger Than 13 Years. JAMA Ophthalmol. 2022;140(3):269-276. (Published).
(Manuscript) | View Publication

6. Bothun ED, Repka MX, Kraker RT, Wu R, Leske DA, Hatt SR, Li Z, Freedman SF, Astle WF, Cotter SA, Holmes JM, on behalf of PEDIG.. Incidence of Glaucoma-related Adverse Events in the First Five Years After Pediatric Lensectomy. JAMA Ophthalmol 2023;141(4):324-331. (Published).
(Manuscript) | View Publication

7. Yen KG, Repka MX, Sutherland DR, Haider KM, Hatt SR, Kraker RT, Galvin JA, Li Z, Cotter SA, Holmes JM; on behalf of PEDIG. Complications Occurring Over Five Years Following Primary Intraocular Lens Implantation for Pediatric Cataract. JAMA Ophthalmol. 2023;141(8):705-714. (Published).
(Manuscript) | View Publication

8. Haider KM, Repka MX, Sutherland DR, Hatt SR, Fallaha N, Kraker RT, Melia BM, Cotter SA, Holmes JM; on behalf of PEDIG.. Outcomes and Complications 5 years Following Surgery for Pediatric Cataract Associated with Persistent Fetal Vasculature. Am J Ophthalmol. 2024;260:30-36. (Published).
(Manuscript) | View Publication

9. Wang S, Repka MX, Sutherland DR, Hatt SR, Traboulsi EI, Lambert SR, Melia BM, Kraker RT, Holmes JM, Cotter SA; on behalf of Pediatric Eye Disease Investigator Group.. Complications, Visual Acuity, and Refractive Error Three Years After Secondary Intraocular Lens implantation for Pediatric Aphakia. Ophthalmology. 2024:131(10);1196-1206. (Published).
(Manuscript) | View Publication

Protocol CCTS - Central Corneal Thickness Study

1. Pediatric Eye Disease Investigator Group. Central Corneal Thickness in Children. Arch Ophthalmol. 2011;129(9):1132-8. (Published).
(Manuscript) | View Publication

2. Bradfield YB, Kaminski BM, Repka MX, Melia M, et al. on behalf of the Pediatric Eye Disease Investigator Group.. Comparison of Tonopen and Goldmann Applanation Tonometers for Measurement of Intraocular Pressure in Healthy Children. J AAPOS. 2012;16(3):242-8. (Published).
(Manuscript) | View Publication

3. Weise KK, Kaminski BM, Melia M, Repka, MX, et al. on behalf of Pediatric Eye Disease Investigator Group. Intraobserver Reliability of Contact Pachymetry in Children. J AAPOS. 2013;17(2):144-8 (Published).
(Manuscript) | View Publication

Protocol CEOS - Congenital Esotropia Observation Study

1. Birch E, Stager D, Wright K, Beck R, Pediatric Eye Disease Investigator Group. The natural history of infantile esotropia during the first six months of life. J AAPOS 1998;2(6):325-8; discussion 329 (Published).
(Manuscript) | View Publication

2. Pediatric Eye Disease Investigator Group. Spontaneous resolution of early-onset esotropia: experience of the Congenital Esotropia Observational Study. Am J Ophthalmol 2002;133(1):109-18 (Published).
(Manuscript) | View Publication

3. Pediatric Eye Disease Investigator Group. The clinical spectrum of early-onset esotropia: experience of the Congenital Esotropia Observational Study. Am J Ophthalmol 2002;133(1):102-8 (Published).
(Manuscript) | View Publication

Protocol CITS - Convergence Insufficiency Treatment Study

1. Pediatric Eye Disease Investigator Group. Home-Based Therapy for Symptomatic Convergence Insufficiency in Children. Optom Vis Sci 2016;93(12):1457-65. (Published).
(Manuscript) | View Publication

Protocol COM02 - Correction of Myopia Evaluation Trial 2

1. Correction of Myopia Evaluation Trial 2 Study Group. Accommodative lag by autorefraction and two dynamic retinoscopy methods. Optom Vis Sci 2009;86(3):233-43 (Published).
(Manuscript) | View Publication

2. Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye Disease Investigator Group. Progressive Addition Lenses versus Single Vision Lenses for Slowing Progression of Myopia in Children with High Accommodative Lag and Near Esophoria. Invest Ophthalmol Vis Sci. 2011 Apr 25;52(5):2749-57. Print 2011 May. (Published).
(Manuscript) | View Publication

Protocol E02 - Esotropia Treatment with Botulinum Toxin-A Injection Data Collection

1. Pediatric Eye Disease Investigator Group. Tonic pupil after botulinum toxin-A injection for treatment of esotropia in children. J AAPOS. Feb 2016;20(1):78-81. (Published).
(Manuscript) | View Publication

Protocol ETS01 - Esotropia Treatment Study 1

1. Pediatric Eye Disease Investigator Group. Instability of ocular alignment in childhood esotropia. Ophthalmology 2008;115(12):2266–74 (Published).
(Manuscript) | View Publication

2. Pediatric Eye Disease Investigator Group. Interobserver reliability of the Prism and Alternate Cover Test in children with esotropia. Arch Ophthalmol 2009;127(1):59-65 (Published).
(Manuscript) | View Publication

3. Pediatric Eye Disease Investigator Group. The relationship between preoperative alignment stability and postoperative motor outcomes in children with esotropia. J AAPOS 2009;13(4):335-8 (Published).
(Manuscript) | View Publication

4. Melia BM, Holmes JM, Chandler DL, Christiansen SP. Classifying angle stability and instability in childhood esotropia. Arch Ophthalmol;128(12):1555-60 (Published).
(Manuscript) | View Publication

Protocol HTS1 - Hyperopia Treatment Study 1

1. Suh DW, Kulp MT, Dean TW, Wallace DK, Kraker RT, Manny RE, Erzurum, SA, Pang Y, Shea, CJ, Avallone JM, on behalf of the Pediatric Eye Disease Investigator Group. Clinical Factors Associated with Moderate Hyperopia in Preschool Children with Normal Stereopsis and Visual Acuity. J AAPOS 2016;20(5):455-7. (Published).
(Manuscript) | View Publication

2. Pediatric Eye Disease Investigator Group; Kulp MT, Holmes JM, Dean TW, Suh DW, Kraker RT, Wallace DK, Petersen DB, Cotter SA, Manny RE, Superstein R, Roberts TL, Avallone JM1, Fishman DR, Erzurum SA, Leske DA, Christoff A.. A Randomized Clinical Trial of Immediate versus Delayed Glasses for Moderate Hyperopia in 1- and 2-Year Olds. Ophthalmology 2019;126(6):876-887. (Published).
(Manuscript) | View Publication

3. Pediatric Eye Disease Investigator Group. Holmes JM, Kulp MT, Dean TW, Suh DW, Kraker RT, Wallace DK, Petersen DB, Cotter SA, Crouch ER, Lorenzana IJ, Ticho BH, Verderber LC, Weise KK. A randomized clinical trial of immediate versus delayed spectacles for moderate hyperopia in children 3 to 5 years of age. Am J Ophthalmol 2019;208(142):145-159. (Published).
(Manuscript) | View Publication

Protocol IXT1 - Intermittent Exotropia Study 1

1. Donahue SP, Chandler DL, Holmes JM, Arthur BW, Paysse EA, Wallace DK, Petersen DB, Melia BM, Kraker RT, Miller AM, on behalf of the Pediatric Eye Disease Investigator Group. A Randomized Trial Comparing Bilateral Lateral Rectus Recession versus Unilateral Recess and Resect for Basic-Type Intermittent Exotropia. Ophthalmology. 2019;126(2):305-317. (Published).
(Manuscript) | View Publication

2. Repka MX, Chandler DL, Holmes JM, Donahue SP, Hoover DL, Mohney BG, Phillips PH, Stout AU, Ticho, BH, Wallace DK. The Relationship of Age and Other Baseline Factors to Outcome of Initial Surgery for Intermittent Exotropia.. Am J Ophthalmol 2020;212:153-161. (Published).
(Manuscript) | View Publication

3. Holmes JM, Hercinovic A, Melia BM, Leske DA, Hatt SR, Chandler DL, Dean TW, Kraker RT, Enyedi LB, Wallace DK, Donahue SP, Cotter SA on behalf of the Pediatric Eye Disease Investigator Group.. Improvement in health-related quality of life following strabismus surgery for children with intermittent exotropia.. J AAPOS 2021;25(2):82.e1-82.e7. (Published).
(Manuscript) | View Publication

Protocol IXT1Ext - Intermittent Exotropia Study 1 Extended Follow Up

1. Donahue SP, Chandler DL, Wu R, Marsh JD, Law C, Areaux RG Jr, Ghasia FF, Li Z, Kraker RT, Cotter SA, Holmes JM; on behalf of PEDIG.. Eight-Year Outcomes of Bilateral Lateral Rectus Recessions versus Unilateral Recess-Resect in Childhood Basic-Type Intermittent Exotropia. Ophthalmology 2024;131(1):95-106. (Published).
(Manuscript) | View Publication

Protocol IXT2 - Intermittent Exotropia Study 2

1. Pediatric Eye Disease Investigator Group. A randomized trial comparing part-time patching with observation for children 3-10 years old with intermittent exotropia. Ophthalmology. Dec 2014;121(12):2299-310 (Published).
(Manuscript) | View Publication

2. Leske DA, Holmes JM, Melia BM, on behalf of Pediatric Eye Disease Investigator Group. Evaluation of the Intermittent Exotropia Questionnaire using Rasch analysis. JAMA Ophthalmol. Apr 2015;133(4):461-5. (Published).
(Manuscript) | View Publication

3. Pediatric Eye Disease Investigator Group. A randomized trial comparing part-time patching with observation for intermittent exotropia in children 12 to 35 months of age. Ophthalmology. Aug 2015;122:1718-25. (Published).
(Manuscript) | View Publication

4. Superstein R, Dean TW, Holmes JM, Chandler DL, Cotter SA, Wallace DK, Melia M; Kraker RT, Weaver RG, Mohney BG, Donahue SP, Birch EE, on behalf of the Pediatric Eye Disease Investigator Group. Relationship among Clinical Factors in Childhood Intermittent Exotropia. J AAPOS 2017;21(4):268-273 (Published).
(Manuscript) | View Publication

5. Mohney BG, Cotter SA, Chandler DL, Holmes JM, Wallace DK, Yamada T, Petersen DB, Kraker RT, Morse CL, Melia BM, Wu R, on behalf of the Pediatric Eye Disease Investigator Group.. Three-year Observation of Children Age 3 to 10 Years Old with Untreated Intermittent Exotropia. Ophthalmology 2019:126(9):1249-1260. (Published).
(Manuscript) | View Publication

6. Cotter SA, Mohney BG, Chandler DL, Holmes JM, Wallace DK, Melia BM, Wu R, Kraker RT, Superstein R, Crouch ER, Paysse EA on behalf of the Pediatric Eye Disease Investigator Group. Three-year observation of children 12 to 35 months old with untreated intermittent exotropia. Ophthalmic Physiol Opt. 2020;40(2):202-215 (Published).
(Manuscript) | View Publication

7. Holmes JM, Hercinovic A, Melia BM, Leske DA, Hatt SR, Chandler DL, Dean TW, Kraker RT, Enyedi LB, Wallace DK, Mohney BG, Cotter SA for the Pediatric Eye Disease Investigator Group.. Health Related quality of life in children with untreated intermittent exotropia and their parents.. J AAPOS. 2021;25(2):80.e1-80.e4. (Published).
(Manuscript) | View Publication

8. Hatt SR, Kraker RT, Leske DA, Chandler DL, Fallaha N, Mohney BG, Ticho BH, Li Z, Cotter SA, Holmes JM.. Improved control of intermittent exotropia with part-time patching. J AAPOS 2023;27(3):160-163. (Published).
(Manuscript) | View Publication

Protocol IXT3 - Intermittent Exotropia Study 3

1. Pediatric Eye Disease Investigator Group. A Randomized Trial Evaluating Short-term Effectiveness of Overminus Lenses in Children 3 to 6 Years of Age with Intermittent Exotropia. Ophthalmology. Oct 2016;123(10):2127-36 (Published).
(Manuscript) | View Publication

Protocol IXT5 - Intermittent Exotropia Study 5

1. Chen AM, Erzurum SA, Chandler DL, Hercinovic A, Melia BM, Bhatt AR, Suh DW, Vricella M, Erickson JW, Miller AM, Marsh JD, Bodack MI, Martinson SR, Titelbaum JR, Gray ME, Holtorf HL, Kong L, Kraker RT, Rahmani B, Shah BK, Holmes JM, Cotter SA; on behalf of the Pediatric Eye Disease Investigator Group.. Overminus Lens Therapy for Children 3 to 10 Years of Age With Intermittent Exotropia: A Randomized Clinical Trial.. JAMA Ophthalmol. 2021;139(4):464-476. (Accepted).
(Manuscript) | View Publication

2. Holmes JM, Leske DA, Hercinovic A, Hatt SR, Chandler DL, Li Z, Melia BM, Chen AM, Erzurum SA, Crouch ER, Jenewein EC, Kraker RT, Cotter SA; on behalf of the Pediatric Eye Disease Investigator Group. Rasch-calibrated Intermittent Exotropia Symptom Questionnaire for Children. Optom Vis Sci 2022;99:513–520. (Published).
(Manuscript) | View Publication

3. Chen AM, Erzurum SA, Chandler DL, Hercinovic A, Wu R, Vricella M, Waters AL, Ticho BH, Erickson JW, Han S, McDowell PS, Li Z, Kraker RT, Holmes JM, Cotter SA; on behalf of PEDIG. Refractive Error Change and Overminus Lens Therapy for Childhood Intermittent Exotropia. JAMA Ophthalmol. 2024;142(5):417-428. (Published).
(Manuscript) | View Publication

Protocol IXT6 - Intermittent Exotropia Study 6

1. Hatt SR, Leske DA, Holmes JM, Henderson RJ, Chandler DL, Morrison DG, Summers AI, Cotter SA; on behalf of the Pediatric Eye Disease Investigator Group. Testing depth of suppression in childhood intermittent exotropia. J AAPOS 2022 Feb;26(1):36-38.e1. (Published).
(Manuscript) | View Publication

2. Summers AI, Morrison DG, Chandler DL, Henderson RJ, Chen AM, Leske DA, Walker KR, Li Z, Melia BM, Bitner DP, Kurup SD, Allen M, Phillips PH, Nash DL, Grigorian AP, Kraus CL, Miller AM, Titelbaum JR, Kraker RT, Holmes JM, Cotter SA; on behalf of PEDIG. A Pilot Randomized Clinical Trial of Relieving Base-in Prism Spectacle Treatment for Intermittent Exotropia. Optom Vis Sci 2023;100(7):432-443. (Published).
(Manuscript) | View Publication

Protocol MTS1 - Myopia Treatment Study 1

1. Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE, Kehler LF, Jordan CO, Raghuram A, Summers AI, Lee KA, Petersen DB, Erzurum SA, Pang Y, Lenhart PD, Ticho BH, Beck RW, Kraker RT, Holmes JM, Cotter SA.. Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial. JAMA Ophthalmol 2023;141(8):756-765. (Published).
(Manuscript) | View Publication

Protocol NLD01 - Nasolacrimal Duct Obstruction 1

1. Pediatric Eye Disease Investigator Group. Primary treatment of nasolacrimal duct obstruction with probing in children younger than 4 years. Ophthalmology 2008;115(3):577-84 (Published).
(Manuscript) | View Publication

2. Pediatric Eye Disease Investigator Group. Primary treatment of nasolacrimal duct obstruction with balloon catheter dilation in children younger than 4 years of age. J AAPOS 2008;12(5):451-5 (Published).
(Manuscript) | View Publication

3. Pediatric Eye Disease Investigator Group. Primary treatment of nasolacrimal duct obstruction with nasolacrimal duct intubation in children younger than 4 years of age. J AAPOS 2008;12(5):445-50 (Published).
(Manuscript) | View Publication

Protocol NLD02 - Nasolacrimal Duct Obstruction 2

1. Pediatric Eye Disease Investigator Group. Balloon catheter dilation and nasolacrimal duct intubation for treatment of nasolacrimal duct obstruction after failed probing. Arch Ophthalmol 2009;127(5):633-9 (Published).
(Manuscript) | View Publication

2. Pediatric Eye Disease Investigator Group. Repeat probing for treatment of persistent nasolacrimal duct obstruction. J AAPOS 2009;13(3):306-7 (Published).
(Manuscript) | View Publication

Protocol NLD03 - Nasolacrimal Duct Obstruction Study 3

1. Pediatric Eye Disease Investigator Group. Resolution of Congenital Nasolacrimal Duct Obstruction with Nonsurgical Management. Arch Ophthalmol. 2012;130(6):730-734 (Published).
(Manuscript) | View Publication

2. Pediatric Eye Disease Investigator Group. A Randomized Trial Comparing the Cost-Effectiveness of Two Approaches for Treating Unilateral Nasolacrimal Duct Obstruction. Arch Ophthalmol 2012;130(12):1525-33 (Published).
(Manuscript) | View Publication

3. Lee KA, Chandler DL, Repka MX, Melia M, Beck RW, Summers CG, Frick KD, Foster NC, Kraker RT, Atkinson S, Avallone JM, on behalf of PEDIG. A Comparison of Treatment Approaches for Bilateral Congenital Nasolacrimal Duct Obstruction. Am J Ophthalmol Nov 2013;156(5):1045-1050. (Published).
(Manuscript) | View Publication

4. Miller AM, Chandler DL, Repka MX, Hoover DL, Lee KA, Melia M, Rychwalski PJ, Silbert DI, on behalf of Pediatric Eye Disease Investigator Group. Office probing for treatment of nasolacrimal duct obstruction in infants. J AAPOS. Feb 2014;18(1):26-30. (Published).
(Manuscript) | View Publication

Protocol PON1 - Pediatric Optic Neuritis

1. Pineles, SL, Liu, GT, Waldman, AT, Lazar, EL, Kupersmith, MJ Repka, MX for the Pediatric Eye Disease Investigator Group and the Neuro-Ophthalmology Research Disease Investigator Consortium. Pediatric Optic Neuritis Prospective Outcomes Study. J Neuroophthalmol: Jun 2016;36(2):115-117 Editorial (Published).
(Manuscript (Non-Peer Reviewed)) | View Publication

2. Pineles SL, Repka MX, Liu GT, Waldman AT, Borchert MS, Khanna S, Heidary G, Graves JS, Shah VS, Kupersmith MJ, Kraker RT, Wallace DK, Cotter SA, Holmes JM on behalf of The Pediatric Eye Disease Investigator Group. Assessment of Pediatric Optic Neuritis Visual Acuity Outcomes at 6 Months. JAMA Ophthalmol 2020;138(12):1253-1261. (Published).
(Manuscript) | View Publication

3. Chen JJ, Pineles SL, Repka MX, Pittock SJ, Henderson RJ, Liu GT.. MOG-IgG Among Participants in the Pediatric Optic Neuritis Prospective Outcomes Study.. JAMA Ophthalmol 2021; 139(5):583-585. (Published).
(Manuscript) | View Publication

4. Pineles SL, Henderson RJ, Repka MX, Heidary G, Liu GT, Waldman AT, Borchert MS, Khanna S, Graves JS, Collinge JE, Conley JA, Davis PL, Kraker RT, Cotter SA, Holmes JM; on behalf of PEDIG. The Pediatric Optic Neuritis Prospective Outcomes Study – Two-Year Results. Ophthalmology 2022;129(8):856-864 (Published).
(Manuscript) | View Publication

Protocol ROP1 - ROP Phase 1

1. Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, Rogers DL. Yang MB, Haider KM, VanderVeen DK, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Hartnett ME; Kong L, Holmes JM, for the Pediatric Eye Disease Investigator Group. Assessment of lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA Ophthalmol 2017;135(6):654-6 (Published).
(Manuscript) | View Publication

2. Wallace DK, Dean TW, Hartnett ME; Kong L, Smith LE, Hubbard GB, McGregor ML, Jordan CO, Mantagos IS, Bell EF, Kraker RT, on behalf of the Pediatric Eye Disease Investigator Group. A Dosing Study of Bevacizumab for ROP: Late Recurrences and Additional Treatments. Ophthalmology. 2018;128(12):1961-1966 (Published).
(Manuscript) | View Publication

3. Crouch ER, Kraker RT, Wallace DK, Holmes JM, Repka MX, Collinge JE, Bremer DL, Gray ME, Smith HA, Steinkuller PG; Writing Committee for the Pediatric Eye Disease Investigator Group.. Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmol. 2020;138(1):14-20. (Published).
(Manuscript) | View Publication

4. Wallace DK, Kraker RT, Freedman SF, Crouch ER, Bhatt AR, Hartnett ME, Yang MB, Rogers DL, Hutchinson AK, VanderVeen DK, Haider KM, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Kong L, Cotter SA, Holmes JM; on behalf of the Pediatric Eye Disease Investigator Group (PEDIG). Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity.. JAMA Ophthalmol. 2020;138(6):698-701. (Published).
(Manuscript) | View Publication

5. Kraker RT, Wallace DK, Beck RW, Saunders CT, Lorenzi E, Melia BM, Li Z; on behalf of PEDIG. Choice of Dose Level for a Randomized Trial of Low-Dose Bevacizumab Versus Laser for Type 1 Retinopathy of Prematurity.. JAMA Ophthalmol. 2021;139(10):1143-1144. (Published).
(Manuscript) | View Publication

6. Hartnett MD, Wallace DK, Dean TW, Li Z, Boente CS, Dosunmu EO, Freedman SF, Golden RP, Kong L, Prakalapakorn SG, Repka MX, Smith LE, Wang H, Kraker RT, Cotter SA, Holmes JM; on behalf of the Pediatric Eye Disease Investigator Group. Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants. JAMA Ophthalmol 2022 Apr 1;140(4):337-344. (Published).
(Manuscript) | View Publication

7. Freedman SF, Hercinovic A, Wallace DK, Kraker RT, Li Z, Bhatt AR, Boente CS, Crouch ER, Hubbard GB, Rogers DL, VanderVeen D, Yang MB, Cheung NL, Cotter SA, Holmes JM; on behalf of PEDIG. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes. Ophthalmology 2022;129(10):1120-1128. (Published).
(Manuscript) | View Publication

8. Wallace DK, Hercinovic A, Freedman SF, Crouch ER, Bhatt AR, Hartnett ME, Yang MB, Rogers DL, Hutchinson AK, Good WV, Repka MX, Li Z, Beck RW, Kraker RT, Cotter SA, Holmes JM on behalf of PEDIG.. Ocular and Developmental Outcomes of a Dosing Study of Bevacizumab for Retinopathy of Prematurity. J AAPOS 2023. 27(1):10.e1-10.e8. (Published).
(Manuscript) | View Publication

Protocol SAS1 - Study of Adult Strabismus

1. Crouch ER, Dean TW, Kraker RT, Miller AM, Kraus CL, Gunton KB, Repka MX, Marsh JD, Del Monte MA, Luke PA, Peragallo JH, Lee KA, Wheeler MB, Daley TJ, Wallace DK, Cotter SA, Holmes JM; on behalf of PEDIG. A prospective study of treatments for adult-onset divergence insufficiency–type esotropia.. J AAPOS. 2021;25(4):203.e1-203.e11 (Published).
(Manuscript) | View Publication

2. Lorenzana IJ, Leske DA, Hatt SR, Dean TW, Jenewein EC, Dagi LR, Beal CJ, Pang Y, Retnasothie DV, Esposito CA, Erzurum SA, Aldrich AE, Crouch ER, Li Z, Kraker RT, Holmes JM, Cotter SA; on behalf of PEDIG. Relationships Among Clinical Factors and Patient-Reported Outcome Measures in Adults with Convergence Insufficiency. Optom Vis Sci 2022;99(9):692-701 (Published).
(Manuscript) | View Publication

3. Miller AM, Holmes JM, Wu R, Kraker RT, Crouch ER, Lee KA, Del Monte MA, Marsh JD, Kraus CL, Wallace DK, Colburn JD, Kemp PS, Cotter SA; on behalf of PEDIG. Doses of Medial Rectus Muscle Recessions for Divergence Insufficiency Type Esotropia. J AAPOS. 2024 Jun;28(3):103905. (Published).
(Manuscript) | View Publication

Protocol X03 - Chalazia Pilot

1. Erzurum SA, Wu R, Melia BM, Li Z, Arnold RW, Silbert DI, Erickson JW, Sala NA, Kraker RT, Holmes JM, Cotter SA; on behalf of PEDIG. Parent-provided photographs as an outcome measure for childhood chalazia. J AAPOS 2022 Apr;26(2):60.e1-60.e5. (Published).
(Manuscript) | View Publication